These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 18649931)

  • 1. High-dose-intensity MVAC for Advanced Renal Medullary Carcinoma: Report of Three Cases and Literature Review.
    Rathmell WK; Monk JP
    Urology; 2008 Sep; 72(3):659-63. PubMed ID: 18649931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal medullary carcinoma: case report and review of the literature.
    Noguera-Irizarry WG; Hibshoosh H; Papadopoulos KP
    Am J Clin Oncol; 2003 Oct; 26(5):489-92. PubMed ID: 14528077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of cisplatin and methotrexate after M-VAC chemotherapy for advanced urothelial cancer in hemodialysis patients.
    Matsumoto K
    Int J Urol; 2008 Oct; 15(10):949-50. PubMed ID: 19138292
    [No Abstract]   [Full Text] [Related]  

  • 4. Prolonged survival of a patient with sickle cell trait and metastatic renal medullary carcinoma.
    Pirich LM; Chou P; Walterhouse DO
    J Pediatr Hematol Oncol; 1999; 21(1):67-9. PubMed ID: 10029817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy has potential to prevent recurrence of bladder tumors after surgical removal of upper urinary tract transitional cell carcinoma.
    Soga N; Arima K; Sugimura Y
    Int J Urol; 2008 Sep; 15(9):800-3. PubMed ID: 18651862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Two cases of urothelial cancer responsive to high-dose-intensity methotrexate vinblastine doxorubicin and cisplatin (M-VAC) therapy].
    Fukuda H; Mitsumori K; Minagawa S; Kumazawa T; Tadachi K; Iinuma M; Satoh S; Satoh K; Habuchi T; Kato T
    Hinyokika Kiyo; 2005 Feb; 51(2):113-6. PubMed ID: 15773365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Possible survival benefit of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin combination therapy (HD-MVAC) over conventional MVAC in metastatic urothelial carcinoma patients.
    Inoue T; Obara T; Saito M; Kumazawa T; Yuasa T; Matuura S; Tsuchiya N; Satoh S; Habuchi T
    Hinyokika Kiyo; 2007 Sep; 53(9):613-8. PubMed ID: 17933135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preliminary results of M-VAC chemotherapy combined with mild hyperthermia, a new therapeutic strategy for advanced or metastatic transitional cell carcinoma of the urothelium.
    Yamada Y; Itoh Y; Aoki S; Nakamura K; Taki T; Naruse K; Tobiume M; Zennami K; Katsuda R; Kato Y; Watanabe M; Nishikawa G; Minami M; Nakahira M; Ukai S; Sawada M; Kitamura A; Honda N
    Cancer Chemother Pharmacol; 2009 Nov; 64(6):1079-83. PubMed ID: 19277660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metastatic renal cell carcinoma arising in a congenital solitary kidney. Treatment with interferon-containing combinations. A case report and a review of the literature.
    Merimsky O; Laufer R; Chaitchik S
    J Urol (Paris); 1989; 95(4):243-5. PubMed ID: 2529317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy for renal cell carcinoma.
    Amato RJ
    Semin Oncol; 2000 Apr; 27(2):177-86. PubMed ID: 10768596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early versus late intensification for patients with high-risk Hodgkin lymphoma-3 cycles of intensive chemotherapy plus low-dose lymph node radiation therapy versus 4 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine plus myeloablative chemotherapy with autologous stem cell transplantation: five-year results of a randomized trial on behalf of the GOELAMS Group.
    Arakelyan N; Berthou C; Desablens B; de Guibert S; Delwail V; Moles MP; Quittet P; Jais JP; Colonna P; Andrieu JM;
    Cancer; 2008 Dec; 113(12):3323-30. PubMed ID: 18988286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A case of primary urotherial carcinoma with glandular differentiation of the renal pelvis with high serum level of carbohydrate antigen 19-9 (CA19-9)].
    Itami Y; Shimizu N; Hayashi T; Nagai Y; Kobayashi Y; Yamamoto Y; Minami T; Nozawa M; Yoshimura K; Ishii T; Uemura H
    Hinyokika Kiyo; 2012 Apr; 58(4):203-7. PubMed ID: 22684261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic chemotherapy options for metastatic bladder cancer.
    Siefker-Radtke A
    Expert Rev Anticancer Ther; 2006 Jun; 6(6):877-85. PubMed ID: 16761931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term survival after combined modality treatment in metastatic bladder cancer patients presenting with supra-regional tumor positive lymph nodes only.
    de Vries RR; Nieuwenhuijzen JA; Meinhardt W; Bais EM; Horenblas S
    Eur J Surg Oncol; 2009 Apr; 35(4):352-5. PubMed ID: 18722076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant therapy in pediatric patients with completely resected renal cell carcinoma.
    Geller JI; Dome JS
    Pediatr Blood Cancer; 2006 Apr; 46(4):527. PubMed ID: 16365852
    [No Abstract]   [Full Text] [Related]  

  • 16. [Chemotherapy of renal cell carcinoma. 2. Combined chemotherapy using ACNU and VBL].
    Kobayashi M; Imai K; Nakai K; Kumasaka F; Suzuki T; Ito Y; Yamanaka H; Sugihara S
    Hinyokika Kiyo; 1986 Mar; 32(3):375-83. PubMed ID: 3460318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Circumvention of the multidrug-resistance in renal cancer by bisbenzylisoquinoline].
    Kakehi Y; Hashimura T; Yoshida O; Segawa T; Kanematsu A
    Hinyokika Kiyo; 1993 Dec; 39(12):1227-32. PubMed ID: 8285174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer.
    Tsuchiya N; Inoue T; Narita S; Kumazawa T; Saito M; Obara T; Tsuruta H; Horikawa Y; Yuasa T; Satoh S; Habuchi T
    J Urol; 2008 Dec; 180(6):2389-95. PubMed ID: 18930278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytologic features of renal medullary carcinoma.
    Assad L; Resetkova E; Oliveira VL; Sun W; Stewart JM; Katz RL; Caraway NP
    Cancer; 2005 Feb; 105(1):28-34. PubMed ID: 15593260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vinorelbine and oxaliplatin in stage IV nonsmall cell lung cancer patients unfit for cisplatin: a single-center experience.
    Mir O; Alexandre J; Ropert S; Montheil V; Martin I; Durand JP; Goldwasser F
    Anticancer Drugs; 2009 Feb; 20(2):105-8. PubMed ID: 19209026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.